Drugs / diflunisal
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Attrogy | — | 2025-07-17 | europa.eu ↗ |
| Approved | US (FDA) | DOLOBID | — | 1982-04-19 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04113668 | Oct → Nov 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00506298 | Jul 2007 → Apr 2009 | type 2 diabetes mellitus | Zalicus | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01676363 | Mar 2013 → Oct 2016 | HIV infectious disease | University of British Columbia | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00294671 Comparator | Feb 2006 → Dec 2012 | familial amyloid neuropathy | Boston University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | diflunisal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04113668 ↗ |
| Known as | Dolobid | ChEMBL registry synonym — accepted as the source's own label CHEMBL898 ↗ |
| Known as | Dolobid 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL898 ↗ |
| Known as | NSC-756728 | ChEMBL registry synonym — accepted as the source's own label CHEMBL898 ↗ |
| Action | Inhibit | “UGT1A9 inhibitor DIFLUNISAL” NCT04113668 ↗ |
| Modality | Small molecule | — CHEMBL898 ↗ |
| Route | Oral | “Diflunisal 250 mg po bid” NCT00294671 ↗ |
| Target | TTR | “Previous in vitro (in a test tube) studies have shown that a common anti-inflammatory drug called diflunisal stabilizes TTR, preventing the formation of amyloid fibrils.” NCT00294671 ↗ |